Announcing the TCT 2016 Press Conference Schedule

Newswise — NEW YORK, NY – September 26, 2016 – The Cardiovascular Research Foundation (CRF) has announced the press conference schedule for late-breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 29 – November 2 in Washington, DC.

Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Sunday, October 30; Monday, October 31; Tuesday, November 1; and Wednesday, November 2.

The complete agenda for TCT 2016 is also available online. Browse through a wide array of topics and learn more about individual sessions, presentations, and faculty on the TCT Web site.

Media are invited to attend TCT. If you are unable to attend in person, you may still cover it remotely via Virtual TCT. Registering as media ensures that you have access to all of the press conferences, trial data, abstracts, and press releases. More information on press credentials and guidelines can be found at http://www.crf.org/tct/press/press-credentials-and-guidelines. To apply for press credentials, visit: http://www.crf.org/tct/press/press-registration-form.

Sunday, October 30, 20167:30 AM - 9:00 AMModerator: Ajay J. Kirtane, MD, SMDiscussants: Neal S. Kleiman, MD; Marie-Claude Morice, MD; Paul S. Teirstein, MD

7:30 AM ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs. IVUS-Guided vs. Angio-Guided Stent Implantation in Patients with Coronary Artery DiseaseZiad A. Ali, MD DPhil

7:45 AMBIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients with Coronary Artery DiseaseClemens von Birgelen, MD, PhD

8:00 AM BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs. a Zotarolimus-Eluting Stent in a More-Comers Population of Patients with Coronary Artery DiseaseDavid E. Kandzari, MD

8:15 AMABSORB China: Two-Year Clinical Outcomes from a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs. an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery DiseaseRunlin Gao, MD

8:30 AM ABSORB II: Three-Year Clinical Outcomes from a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs. an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery DiseasePatrick W. Serruys, MD, PhD

8:45 AM LEADERS FREE: Two-Year Clinical and Subgroup Outcomes from a Prospective, Randomized Trial of a Polymer-Free Drug-Coated Stent and a Bare Metal Stent in Patients with Coronary Artery Disease at High Bleeding RiskPhilip M. Urban, MD

Monday, October 31, 20167:30 AM - 9:15 AM

Moderator: Roxana Mehran, MDDiscussants: David J. Cohen, MD; Dean J. Kereiakes, MD; Michael J. Mack, MD

7:30 AM EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery DiseaseGregg W. Stone, MD

7:45 AMNOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery DiseaseEvald H. Christiansen, PhD

8:00 AM REVELUTION: 9-Month Clinical, Angiographic, IVUS, and OCT Outcomes with a Polymer-Free Sirolimus-Eluting Drug-Filled StentStephen G. Worthley, MBBS, PhD

8:15 AMFANTOM II: 6-Month and 9-Month Clinical, Angiographic and OCT Results with a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery DiseaseAlexandre Abizaid, MD, PhD

8:30 AMMeRes-1: 6-Month Clinical, Angiographic, IVUS and OCT Results with a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery DiseaseAshok Seth, MBBS, DSc, DLitt

8:45 AMFORTITUDE: 9-Month Clinical, Angiographic, and OCT Results with an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery DiseaseAntonio Colombo, MD

9:00 AM FUTURE-I: 6-Month Clinical, Angiographic, IVUS and OCT Results with a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery DiseaseXu Bo, MD

Tuesday, November 1, 20167:30 AM - 9:30 AM

Moderator: George D. Dangas, MD, PhDDiscussants: David H. Adams, MD; David R. Holmes Jr., MD; Jeffrey J. Popma, MD

7:30 AMSENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve ReplacementSusheel Kodali, MD

7:45 AM PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate Risk Patients with Severe Aortic StenosisDavid J. Cohen, MD

8:00 AM PARTNER I FIVE-YEAR ECHO: Long-Term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients with Aortic StenosisPamela S. Douglas, MD

8:15 AMRESPECT; Final Long-Term Outcomes From a Prospective, Randomized Trial of PFO Closure in Patients with Cryptogenic StrokeDavid E. Thaler, MD, PhD

8:30 AMCOLOR: A Prospective, Multicenter Registry Evaluating the Relationship Between Lipid-Rich Plaque and Two-Year Outcomes after Stent Implantation in Patients with Coronary Artery DiseaseGiora Weisz, MD

8:45 AM PLATINUM DIVERSITY: Outcomes from a Large-Scale, Prospective Registry of Coronary Artery Stent Implantation in Women and MinoritiesWayne B. Batchelor, MD, MHS

9:00 AMReACT: A Prospective, Randomized Trial of Routine Angiographic Follow-up After Coronary Artery Stent ImplantationHiroki Shiomi, MD

9:15 AM WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results with a Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial FibrillationVivek Y. Reddy, MD

Wednesday, November 2, 20167:30 AM - 9:00 AMModerator: Ori Ben-Yehuda, MDDiscussants: William A. Gray, MD; Michael R. Jaff, DO; Mark Reisman, MD; Christopher Metzger, MD

7:30 AM ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal ArteriesSean P. Lyden, MD

7:45 AM AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results with a Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial FibrillationDavid Hildick-Smith, MD

8:00 AMPRISON IV: A Prospective, Randomized Trial of a Bioresorbable Polymer-Based Sirolimus-Eluting Stent and a Durable Polymer-Based Everolimus-Eluting Stent in Patients with Coronary Artery Chronic Total OcclusionsKoen Teeuwen, MD

8:15 AM TOSCA-5: A Prospective, Randomized Trial Evaluating Collagenase Infusion in Patients with Coronary Artery Chronic Total OcclusionsChristopher E. Buller, MD

8:30 AMTRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at 3 Months and Neoatherosclerosis at 18 Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting StentsGiulio Guagliumi, MD

8:45 AMRIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis – 6-9 Month Clinical and Angiographic Follow-up ResultsFernando Alfonso, MD, PhD

Receive updates on Twitter at http://twitter.com/TCTConference and http://twitter.com/crfheart.

About CRF and TCTThe Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and has educated doctors on the latest treatments for heart disease.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. Now in its 28th year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field. For more information, visit www.crf.org and www.tctconference.com.

###